This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Camphausen, K. Articles by Tofilon, P. J. Search for Related Content PubMed PubMed Citation Articles by Camphausen, K. Articles by Tofilon, P. J.

Enhanced Radiation-Induced Cell Killing and Prolongation of H2AX Foci Expression by the Histone Deacetylase Inhibitor MS-275

¹Radiation Oncology Branch and ²Molecular Radiation Therapeutics Branch, Radiation Oncology Sciences Program, ³Medicine Branch, National Cancer Institute, Bethesda, Maryland

Histone deacetylase (HDAC) inhibitors are undergoing clinical evaluation for cancer therapy. Because HDAC modulates chromatin structure and gene expression, parameters considered to influence radioresponse, we have investigated the effects of the HDAC inhibitor MS-275 on the radiosensitivity of two human tumor cell lines (DU145 prostate carcinoma and U251 glioma). Acetylation status of histones H3 and H4 was determined as a function of time after MS-275 addition to and removal from culture medium. Histone acetylation increased by 6 h after MS-275 addition, reaching a maximum between 24 and 48 h of exposure; providing fresh drug-free medium then resulted in a decrease in histone acetylation that began by 6 h and approached untreated levels by 16 h. Treatment of cells with MS-275 for 48 h followed by irradiation had little or no effect on radiation-induced cell death. However, exposure to MS-275 before and after irradiation resulted in an increase in radiosensitivity with dose enhancement factors of 1.9 and 1.3 for DU145 and U251 cells, respectively. This MS-275 treatment protocol did not result in a redistribution of the cells into a more radiosensitive phase of the cell cycle or in an increase in apoptosis. However, MS-275 did modify the time course of H2AX expression in irradiated cells. Whereas there was no significant difference in radiation-induced H2AX foci at 6 h, the number of cells expressing H2AX foci was significantly greater in the MS-275-treated cells at 24 h after irradiation. These results indicate that MS-275 can enhance radiosensitivity and suggest that this effect may involve an inhibition of DNA repair.

This article has been cited by other articles:

				A. Baschnagel, A. Russo, W. E. Burgan, D. Carter, K. Beam, D. Palmieri, P. S. Steeg, P. Tofilon, and K. Camphausen Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro and as intracranial xenografts Mol. Cancer Ther., June 1, 2009; 8(6): 1589 - 1595. [Abstract] [Full Text] [PDF]

				P. Chinnaiyan, D. Cerna, W. E. Burgan, K. Beam, E. S. Williams, K. Camphausen, and P. J. Tofilon Postradiation Sensitization of the Histone Deacetylase Inhibitor Valproic Acid Clin. Cancer Res., September 1, 2008; 14(17): 5410 - 5415. [Abstract] [Full Text] [PDF]

				W. J. Kil, D. Cerna, W. E. Burgan, K. Beam, D. Carter, P. S. Steeg, P. J. Tofilon, and K. Camphausen In vitro and In vivo Radiosensitization Induced by the DNA Methylating Agent Temozolomide Clin. Cancer Res., February 1, 2008; 14(3): 931 - 938. [Abstract] [Full Text] [PDF]

				S. Adimoolam, M. Sirisawad, J. Chen, P. Thiemann, J. M. Ford, and J. J. Buggy HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination PNAS, December 4, 2007; 104(49): 19482 - 19487. [Abstract] [Full Text] [PDF]

				C. A. Banuelos, J. P. Banath, S. H. MacPhail, J. Zhao, T. Reitsema, and P. L. Olive Radiosensitization by the Histone Deacetylase Inhibitor PCI-24781 Clin. Cancer Res., November 15, 2007; 13(22): 6816 - 6826. [Abstract] [Full Text] [PDF]

				K. Camphausen and P. J. Tofilon Inhibition of Histone Deacetylation: A Strategy for Tumor Radiosensitization J. Clin. Oncol., September 10, 2007; 25(26): 4051 - 4056. [Abstract] [Full Text] [PDF]

				N. Keshelava, E. Davicioni, Z. Wan, L. Ji, R. Sposto, T. J. Triche, and C. P. Reynolds Histone Deacetylase 1 Gene Expression and Sensitization of Multidrug-Resistant Neuroblastoma Cell Lines to Cytotoxic Agents by Depsipeptide J Natl Cancer Inst, July 18, 2007; 99(14): 1107 - 1119. [Abstract] [Full Text] [PDF]

				L. Geng, K. C. Cuneo, A. Fu, T. Tu, P. W. Atadja, and D. E. Hallahan Histone Deacetylase (HDAC) Inhibitor LBH589 Increases Duration of {gamma}-H2AX Foci and Confines HDAC4 to the Cytoplasm in Irradiated Non-Small Cell Lung Cancer Cancer Res., December 1, 2006; 66(23): 11298 - 11304. [Abstract] [Full Text] [PDF]

				B. Sanchez-Gonzalez, H. Yang, C. Bueso-Ramos, K. Hoshino, A. Quintas-Cardama, V. M. Richon, and G. Garcia-Manero Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor Blood, August 15, 2006; 108(4): 1174 - 1182. [Abstract] [Full Text] [PDF]

				A. Munshi, T. Tanaka, M. L. Hobbs, S. L. Tucker, V. M. Richon, and R. E. Meyn Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of {gamma}-H2AX foci. Mol. Cancer Ther., August 1, 2006; 5(8): 1967 - 1974. [Abstract] [Full Text] [PDF]

				I. A. Kim, J. H. Shin, I. H. Kim, J. H. Kim, J. S. Kim, H. G. Wu, E. K. Chie, S. W. Ha, C. I. Park, and G. D. Kao Histone Deacetylase Inhibitor-Mediated Radiosensitization of Human Cancer Cells: Class Differences and the Potential Influence of p53 Clin. Cancer Res., February 1, 2006; 12(3): 940 - 949. [Abstract] [Full Text] [PDF]

				M. Entin-Meer, A. Rephaeli, X. Yang, A. Nudelman, S. R. VandenBerg, and D. A. Haas-Kogan Butyric acid prodrugs are histone deacetylase inhibitors that show antineoplastic activity and radiosensitizing capacity in the treatment of malignant gliomas Mol. Cancer Ther., December 1, 2005; 4(12): 1952 - 1961. [Abstract] [Full Text] [PDF]

				R. L. Bevins and S. G. Zimmer It's About Time: Scheduling Alters Effect of Histone Deacetylase Inhibitors on Camptothecin-Treated Cells Cancer Res., August 1, 2005; 65(15): 6957 - 6966. [Abstract] [Full Text] [PDF]

				R. V. Nome, A. Bratland, G. Harman, O. Fodstad, Y. Andersson, and A. H. Ree Cell cycle checkpoint signaling involved in histone deacetylase inhibition and radiation-induced cell death Mol. Cancer Ther., August 1, 2005; 4(8): 1231 - 1238. [Abstract] [Full Text] [PDF]

				A. Munshi, J. F. Kurland, T. Nishikawa, T. Tanaka, M. L. Hobbs, S. L. Tucker, S. Ismail, C. Stevens, and R. E. Meyn Histone Deacetylase Inhibitors Radiosensitize Human Melanoma Cells by Suppressing DNA Repair Activity Clin. Cancer Res., July 1, 2005; 11(13): 4912 - 4922. [Abstract] [Full Text] [PDF]

				H. Dote, D. Cerna, W. E. Burgan, D. J. Carter, M. A. Cerra, M. G. Hollingshead, K. Camphausen, and P. J. Tofilon Enhancement of In vitro and In vivo Tumor Cell Radiosensitivity by the DNA Methylation Inhibitor Zebularine Clin. Cancer Res., June 15, 2005; 11(12): 4571 - 4579. [Abstract] [Full Text] [PDF]

				M. K. Lee, M. P. Hande, and K. Sabapathy Ectopic mTERT expression in mouse embryonic stem cells does not affect differentiation but confers resistance to differentiation- and stress-induced p53-dependent apoptosis J. Cell Sci., February 15, 2005; 118(4): 819 - 829. [Abstract] [Full Text] [PDF]

				L.-C. Li, P. R. Carroll, and R. Dahiya Epigenetic Changes in Prostate Cancer: Implication for Diagnosis and Treatment J Natl Cancer Inst, January 19, 2005; 97(2): 103 - 115. [Abstract] [Full Text] [PDF]

				K. Camphausen, T. Scott, M. Sproull, and P. J. Tofilon Enhancement of Xenograft Tumor Radiosensitivity by the Histone Deacetylase Inhibitor MS-275 and Correlation with Histone Hyperacetylation Clin. Cancer Res., September 15, 2004; 10(18): 6066 - 6071. [Abstract] [Full Text] [PDF]